Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;18(10):1993-2002.
doi: 10.1002/alz.12655. Epub 2022 Mar 16.

Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation

Harald Hampel  1 , Andrea Vergallo  1 , Takeshi Iwatsubo  2 , Min Cho  1 , Kiyoshi Kurokawa  3 , Huali Wang  4 , H Ricky Kurzman  1 , Christopher Chen  5
Affiliations

Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation

Harald Hampel et al. Alzheimers Dement. 2022 Oct.

Abstract

With population growth and aging, the number of people with dementia and related disorders will grow substantially in the years ahead, bringing with it significant societal, health-care, and economic challenges. Here, we analyze dementia policies of seven major countries in Asia/Pacific, Europe, and North America to identify opportunities for early actions to mitigate disease burden. We find that most countries are addressing this need by including a specific focus on early action in their national dementia strategies (five of seven countries), implementing public health initiatives for risk reduction, prevention, and early detection and diagnosis (six of seven countries); supporting enabling research for early detection and risk reduction (six of seven countries); and enacting a system for early, regular brain health screening (one of seven). We discuss risks and opportunities for integrating early action policies and conducting additional systematic research to understand the potential benefits and impacts of these policies.

PubMed Disclaimer

Conflict of interest statement

HH is an employee of Eisai Inc. He serves as Senior Associate Editor for the journal Alzheimer's & Dementia and has not received any fees or honoraria since May 2019; before May 2019 he had received lecture fees from Servier, Biogen, and Roche; research grants from Pfizer, Avid, and MSD Avenir (paid to the institution); travel funding from Eisai, Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE‐Healthcare and Oryzon Genomics; consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation; and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics, and Roche Diagnostics. He is inventor of 11 patents and has received no royalties: (1) In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388; (2) In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784; (3) Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300; (4) In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463; (5) In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286; (6) In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822; (7) In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553; (8) CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797; (9) In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966; (10) Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921; (11) Method for diagnosis of dementia and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid: Publication number: United States Patent 10921330. AV is an employee of Eisai Inc. He has not received any fees or honoraria since November 2019. Before November 2019, he had received lecture honoraria from Roche, MagQu LLC, and Servier. MC and HRK are employees of Eisai Inc. HW has provided consultation to Eisai Inc., Lundbeck, Roche, and Signant Health pharmaceutical and assessment companies. HW owns the copyright of the individualized management system of neuropsychiatric symptoms (NPSIMS). CC has provided consultation to Cerecin, Danone, Eisai Inc., Lundbeck, Moleac, and Senescence. TI and KK have no conflicts to report.

References

    1. Dementia. World Health Organization. September 2, 2021. Accessed January 11, 2022. https://www.who.int/news‐room/fact‐sheets/detail/dementia
    1. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413‐446. - PMC - PubMed
    1. New blood test to identify people at risk of developing Alzheimer’s symptoms will be used in clinical trial aiming to prevent memory loss. PRNewswire. November 11, 2021. Accessed January 10, 2022. https://www.prnewswire.com/news‐releases/new‐blood‐test‐to‐identify‐peop...
    1. Kirmess KM, Meyer MR, Holubasch MS, et al. The PrecivityAD™ test: Accurate and reliable LC‐MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clinica Chimica Acta. 2021:519:267‐275. 10.1016/j.cca.2021.05.011 - DOI - PMC - PubMed
    1. Stroud C, Onnela J, Manji H. Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders. npj Digit Med. 2019;2(1). 10.1038/s41746-019-0123-z - DOI - PMC - PubMed